|
Q3 FY2026
As of Apr 30, 2026
|
Q2 FY2026
As of Jan 31, 2026
|
Q1 FY2026
As of Oct 31, 2025
|
Q4 FY2025
As of Jul 31, 2025
|
Q3 FY2025
As of Apr 30, 2025
|
Q2 FY2025
As of Jan 31, 2025
|
Q1 FY2025
As of Oct 31, 2024
|
Q4 FY2024
As of Jul 31, 2024
|
Q3 FY2024
As of Apr 30, 2024
|
Q2 FY2024
As of Jan 31, 2024
|
Q1 FY2024
As of Oct 31, 2023
|
Q4 FY2023
As of Jul 31, 2023
|
Q3 FY2023
As of Apr 30, 2023
|
Q2 FY2023
As of Jan 31, 2023
|
Q1 FY2023
As of Oct 31, 2022
|
Q4 FY2022
As of Jul 31, 2022
|
Q3 FY2022
As of Apr 30, 2022
|
Q2 FY2022
As of Jan 31, 2022
|
Q1 FY2022
As of Oct 31, 2021
|
Q4 FY2021
As of Jul 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Inventories, net | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ deficiency | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Convertible notes payable to related parties, current | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total convertible notes payable to related parties, current | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| Accrued liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Note payable to related parties | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total note payable to related parties | ||||||||||||||||||||
| Convertible notes payable to related parties, non-current | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total convertible notes payable to related parties, non-current | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ deficiency | ||||||||||||||||||||
| Common stock, $0.01 par value: 200,000,000 shares authorized, 130,017,569 shares issued and outstanding at April 30, 2026, and 111,886,473 at July 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ deficiency | ||||||||||||||||||||
| Total liabilities and stockholders’ deficiency | ||||||||||||||||||||
Loading...
